dextroamphetamine saccharate amphetamine aspartate monohydrate dextroamphetamine sulfate amphetamine sulfate 30 mg

1 INDICATIONS AND USAGE Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules, a CNS stimulant, are indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older. (1) 1.1 Attention Deficit Hyperactivity Disorder Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules are indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older.

sun pharmaceutical industries, inc.

FDA Reported Adverse Reactions
`[1] nausea` `[2] diarrhoea` `[3] fatigue` `[4] drug ineffective` `[5] dyspnoea` `[6] pain` `[7] vomiting` `[8] headache` `[9] off label use` `[10] dizziness`

2 years ago

CAPSULE ORANGE 341 30 mg

16 HOW SUPPLIED/STORAGE AND HANDLING

DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE extended-release capsules are available as: 5 mg extended-release capsules: light blue colored opaque cap and naturally transparent body imprinted with ‘336’ on cap and ‘5 mg’ on body in black ink containing light orange colored pellets. NDC : 57664-336-88 100 count CRC 10 mg extended-release capsules: powder blue colored opaque cap and body imprinted with ‘337’ on cap and ‘10 mg’ on body in black ink containing light orange colored pellets. NDC : 57664-337-88 100 count CRC 15 mg extended-release capsules: white colored opaque cap and powder blue transparent body imprinted with ‘338’ on cap and ‘15 mg’ on body in black ink containing light orange colored pellets. NDC : 57664-338-88 100 count CRC 20 mg extended-release capsules: medium orange opaque colored cap and body imprinted with ‘339’ on cap and ‘20 mg’ on body in black ink containing light orange colored pellets. NDC : 57664-339-88 100 count CRC 25 mg extended-release capsules: white colored opaque cap and medium orange colored opaque body imprinted with ‘340’ on cap and ‘25 mg’ on body in black ink containing light orange colored pellets. NDC : 57664-340-88 100 count CRC 30 mg extended-release capsules: medium orange colored opaque cap and naturally transparent body imprinted with ‘341’ on cap and ‘30 mg’ on body in black ink containing light orange colored pellets. NDC : 57664-341-88 100 count CRC Dispense in a tight, light-resistant container as defined in the USP. Store at 20°-25° C (68°-77° F). Excursions permitted to 15°- 30° C (59°-86° F) [see USP Controlled Room Temperature.]

More pills like CAPSULE 341 30 mg

DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site

dextroamphetamine saccharate amphetamine aspartate monohydrate dextroamphetamine sulfate amphetamine sulfate 30 mg

FDA Reported Adverse Reactions [1] nausea [2] diarrhoea [3] fatigue [4] drug ineffective [5] dyspnoea [6] pain [7] vomiting [8] headache [9] off label use [10] dizziness

CAPSULE ORANGE 341 30 mg

More pills like CAPSULE 341 30 mg

FDA Reported Adverse Reactions
`[1] nausea` `[2] diarrhoea` `[3] fatigue` `[4] drug ineffective` `[5] dyspnoea` `[6] pain` `[7] vomiting` `[8] headache` `[9] off label use` `[10] dizziness`